Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Globe Newswire•01/10/2026•02:00 ET
0
Key Highlights
- ➤Oculis (OCS) partners with National MS Society on five-year Campaign to End MS
- ➤Privosegtor PIONEER program includes two registrational optic neuritis trials
- ➤Oculis plans fourth-quarter IND submission for Privosegtor in acute MS relapses
- ➤Privosegtor received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis
- ➤Oculis plans Q4 R&D Day covering Privosegtor and pipeline development programs
Expert Statements
Riad Sherif, Chief Executive Officer of Oculis
“Our sponsorship of the National MS Society's Campaign to End MS marks the beginning of what we believe will be a long-term partnership with an organization that has spent 80 years advancing research and care for people living with MS. We share the Society's commitment to accelerating progress for people affected by MS and, through our Privosegtor development program, we are working to advance a much-needed neuroprotective treatment option for patients experiencing optic neuritis and acute MS relapses.”
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life
Get started
Create a free account to read the full story.